logo

For the Inventor, By the Inventor

Tokyo, Japan

Hiroyuki Enari

This inventor holds 23 USPTO granted patents, plus 3 CIPO patents, primarily in Pharmaceutical Compounds. Top assignees: Kureha Kagaku Kogyo Kabushiki Kaisha, Kureha Chemical Industry Company, Limited, Kureha Kagaku Kogyo K.k.. Active years: 1987-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroyuki Enari. Retrieved from https://idiyas.com/inventor/hiroyuki-enari

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.1

ph-index = 7

Forward Citations = 159(Granted Patents)


Location History:

  • Iwaki, JP (1987 - 1995)
  • Tokyo, JP (1995 - 2001)

Company Filing History:

goldMedal13 out of 776 
 
Kureha Kagaku Kogyo Kabushiki Kaisha
 patents
silverMedal9 out of 128 
 
Kureha Chemical Industry Company, Limited
 patents
bronzeMedal1 out of 137 
 
Kureha Kagaku Kogyo K.k.
 patents

Years Active: 1987-2001

Loading Chart...
Loading Chart...
Areas of Expertise:
Benzimidazole Derivative
Cardiac Diseases
Pharmaceutical Composition
Benzene Derivatives
Pyrimidine Derivatives
Cyclopentanecarboxylic Acid
Oxirane Derivatives
Agricultural Chemicals
Novel Azole Derivative
Fungicidal Compounds
Phenylacetic Ester
Cyclopentanone Derivatives
23 patents (USPTO):Explore Patents
1. 6242445 - Benzimidazole derivative (2001-06-05),
2. 6211175 - Cardiac diseases improving method (2001-04-03),
3. 5932575 - Cardiac diseases improving agents (1999-08-03),
4. 5863913 - Aromatic compound and pharmaceutical composition (1999-01-26),
5. 5739131 - Benzene derivatives and pharmaceutical composition (1998-04-14),
6. 5731310 - Benzene derivatives and pharmaceutical composition (1998-03-24),
7. 5696118 - Benzene derivatives and pharmaceutical composition (1997-12-09),
8. 5637586 - Benzimidazolesulfonamide derivatives and pharmaceutical composition (1997-06-10),
9. 5585381 - Pyrimidine derivatives and pharmaceutical composition (1996-12-17),
10. 5468869 - Process for production of (azolylmethyl)-(biphenylmethyl)cyclopentanol (1995-11-21),
11. 5414105 - Cyclopentanecarboxylic acid derivatives useful for producing azole (1995-05-09),
12. 5401736 - 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid amide (1995-03-28),
13. 5239089 - Oxirane derivatives useful for making fungicidal azole compounds (1993-08-24),
14. 5159118 - Cyclopentanone derivatives (1992-10-27),
15. 5028254 - Azole derivatives and agricultural and horticultural chemical (1991-07-02),

Title: **Hiroyuki Enari: Innovator in Cardiac Disease Treatment**

Introduction

Hiroyuki Enari, based in Tokyo, Japan, is a prominent inventor renowned for his contributions to the field of cardiology through innovative pharmaceutical advancements. With an impressive portfolio of 23 patents, he stands out as a key figure in developing methods to improve cardiac health.

Latest Patents

Among his latest patents are significant findings related to benzimidazole derivatives, which play a crucial role in enhancing treatments for cardiac diseases. These patents demonstrate his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Throughout his career, Hiroyuki has been associated with esteemed companies such as Kureha Kagaku Kogyo Kabushiki Kaisha and Kureha Chemical Industry Company, Limited. His work at these organizations has allowed him to focus on innovative research and the application of his ideas in real-world medical solutions.

Collaborations

Hiroyuki has collaborated with talented colleagues, including Satoru Kumazawa and Mikiro Yanaka, to push the boundaries of what is possible in cardiac disease treatment. Their combined expertise has led to groundbreaking inventions that continue to influence the industry.

Conclusion

Hiroyuki Enari's dedication to innovation in the pharmaceutical sector highlights the vital role that inventors play in improving public health. Through his extensive patent portfolio and collaborative efforts, he remains a significant contributor to advancements in treatment methodologies for cardiac diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…